Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

MFF REGULATION OF MITOCHONDRIAL CELL DEATH IS A THERAPEUTIC TARGET IN CANCER.

Seo JH, Chae YC, Kossenkov AV, Lee YG, Tang HY, Agarwal E, Gabrilovich DI, Languino LR, Speicher DW, Shastrula PK, Storaci AM, Ferrero S, Gaudioso G, Caroli M, Tosi D, Giroda M, Vaira V, Rebecca VW, Herlyn M, Xiao M, Fingerman D, Martorella A, Skordalakes E, Altieri DC.

Cancer Res. 2019 Oct 3. pii: canres.1982.2019. doi: 10.1158/0008-5472.CAN-19-1982. [Epub ahead of print]

PMID:
31582380
2.

Recent advances with cyclin-dependent kinase inhibitors: therapeutic agents for breast cancer and their role in immuno-oncology.

Di Sante G, Pagé J, Jiao X, Nawab O, Cristofanilli M, Skordalakes E, Pestell RG.

Expert Rev Anticancer Ther. 2019 Jul;19(7):569-587. doi: 10.1080/14737140.2019.1615889. Epub 2019 Jun 20.

3.

A non-natural nucleotide uses a specific pocket to selectively inhibit telomerase activity.

Hernandez-Sanchez W, Huang W, Plucinsky B, Garcia-Vazquez N, Robinson NJ, Schiemann WP, Berdis AJ, Skordalakes E, Taylor DJ.

PLoS Biol. 2019 Apr 5;17(4):e3000204. doi: 10.1371/journal.pbio.3000204. eCollection 2019 Apr.

4.

Structural and functional analysis of an OB-fold in human Ctc1 implicated in telomere maintenance and bone marrow syndromes.

Shastrula PK, Rice CT, Wang Z, Lieberman PM, Skordalakes E.

Nucleic Acids Res. 2018 Jan 25;46(2):972-984. doi: 10.1093/nar/gkx1213.

5.

ADAR1 controls apoptosis of stressed cells by inhibiting Staufen1-mediated mRNA decay.

Sakurai M, Shiromoto Y, Ota H, Song C, Kossenkov AV, Wickramasinghe J, Showe LC, Skordalakes E, Tang HY, Speicher DW, Nishikura K.

Nat Struct Mol Biol. 2017 Jun;24(6):534-543. doi: 10.1038/nsmb.3403. Epub 2017 Apr 24.

6.

Structural and functional analysis of the human POT1-TPP1 telomeric complex.

Rice C, Shastrula PK, Kossenkov AV, Hills R, Baird DM, Showe LC, Doukov T, Janicki S, Skordalakes E.

Nat Commun. 2017 Apr 10;8:14928. doi: 10.1038/ncomms14928.

7.

Structural Analysis Reveals the Deleterious Effects of Telomerase Mutations in Bone Marrow Failure Syndromes.

Hoffman H, Rice C, Skordalakes E.

J Biol Chem. 2017 Mar 17;292(11):4593-4601. doi: 10.1074/jbc.M116.771204. Epub 2017 Feb 1.

8.

Crystallographic Studies of Telomerase.

Hoffman H, Skordalakes E.

Methods Enzymol. 2016;573:403-19. doi: 10.1016/bs.mie.2016.04.006. Epub 2016 May 10.

9.

Structure and function of the telomeric CST complex.

Rice C, Skordalakes E.

Comput Struct Biotechnol J. 2016 Apr 14;14:161-7. doi: 10.1016/j.csbj.2016.04.002. eCollection 2016. Review.

10.

SPOP E3 Ubiquitin Ligase Adaptor Promotes Cellular Senescence by Degrading the SENP7 deSUMOylase.

Zhu H, Ren S, Bitler BG, Aird KM, Tu Z, Skordalakes E, Zhu Y, Yan J, Sun Y, Zhang R.

Cell Rep. 2015 Nov 10;13(6):1183-1193. doi: 10.1016/j.celrep.2015.09.083. Epub 2015 Oct 29.

11.

Structural Basis of Telomerase Inhibition by the Highly Specific BIBR1532.

Bryan C, Rice C, Hoffman H, Harkisheimer M, Sweeney M, Skordalakes E.

Structure. 2015 Oct 6;23(10):1934-1942. doi: 10.1016/j.str.2015.08.006. Epub 2015 Sep 10.

12.

The Telomere Binding Protein Cdc13 and the Single-Stranded DNA Binding Protein RPA Protect Telomeric DNA from Resection by Exonucleases.

Greetham M, Skordalakes E, Lydall D, Connolly BA.

J Mol Biol. 2015 Sep 25;427(19):3023-30. doi: 10.1016/j.jmb.2015.08.002. Epub 2015 Aug 8.

13.

Interaction between TBP and Condensin Drives the Organization and Faithful Segregation of Mitotic Chromosomes.

Iwasaki O, Tanizawa H, Kim KD, Yokoyama Y, Corcoran CJ, Tanaka A, Skordalakes E, Showe LC, Noma K.

Mol Cell. 2015 Sep 3;59(5):755-67. doi: 10.1016/j.molcel.2015.07.007. Epub 2015 Aug 6.

14.

Binding of the sphingolipid S1P to hTERT stabilizes telomerase at the nuclear periphery by allosterically mimicking protein phosphorylation.

Panneer Selvam S, De Palma RM, Oaks JJ, Oleinik N, Peterson YK, Stahelin RV, Skordalakes E, Ponnusamy S, Garrett-Mayer E, Smith CD, Ogretmen B.

Sci Signal. 2015 Jun 16;8(381):ra58. doi: 10.1126/scisignal.aaa4998.

15.

LIMD2 is a small LIM-only protein overexpressed in metastatic lesions that regulates cell motility and tumor progression by directly binding to and activating the integrin-linked kinase.

Peng H, Talebzadeh-Farrooji M, Osborne MJ, Prokop JW, McDonald PC, Karar J, Hou Z, He M, Kebebew E, Orntoft T, Herlyn M, Caton AJ, Fredericks W, Malkowicz B, Paterno CS, Carolin AS, Speicher DW, Skordalakes E, Huang Q, Dedhar S, Borden KLB, Rauscher FJ 3rd.

Cancer Res. 2014 Mar 1;74(5):1390-1403. doi: 10.1158/0008-5472.CAN-13-1275.

16.

A motif in the vertebrate telomerase N-terminal linker of TERT contributes to RNA binding and telomerase activity and processivity.

Harkisheimer M, Mason M, Shuvaeva E, Skordalakes E.

Structure. 2013 Oct 8;21(10):1870-8. doi: 10.1016/j.str.2013.08.013. Epub 2013 Sep 19.

17.

Structure of the human telomeric Stn1-Ten1 capping complex.

Bryan C, Rice C, Harkisheimer M, Schultz DC, Skordalakes E.

PLoS One. 2013 Jun 24;8(6):e66756. doi: 10.1371/journal.pone.0066756. Print 2013.

18.

Single cell analysis of RNA-mediated histone H3.3 recruitment to a cytomegalovirus promoter-regulated transcription site.

Newhart A, Rafalska-Metcalf IU, Yang T, Joo LM, Powers SL, Kossenkov AV, Lopez-Jones M, Singer RH, Showe LC, Skordalakes E, Janicki SM.

J Biol Chem. 2013 Jul 5;288(27):19882-99. doi: 10.1074/jbc.M113.473181. Epub 2013 May 20.

19.

Cdc13 OB2 dimerization required for productive Stn1 binding and efficient telomere maintenance.

Mason M, Wanat JJ, Harper S, Schultz DC, Speicher DW, Johnson FB, Skordalakes E.

Structure. 2013 Jan 8;21(1):109-120. doi: 10.1016/j.str.2012.10.012. Epub 2012 Nov 21.

20.

In vitro reconstitution of the active T. castaneum telomerase.

Schuller AP, Harkisheimer MJ, Skordalakes E.

J Vis Exp. 2011 Jul 14;(53):e2799. doi: 10.3791/2799.

21.

Telomerase structure function.

Mason M, Schuller A, Skordalakes E.

Curr Opin Struct Biol. 2011 Feb;21(1):92-100. doi: 10.1016/j.sbi.2010.11.005. Epub 2010 Dec 17. Review.

PMID:
21168327
22.

Neural and synaptic defects in slytherin, a zebrafish model for human congenital disorders of glycosylation.

Song Y, Willer JR, Scherer PC, Panzer JA, Kugath A, Skordalakes E, Gregg RG, Willer GB, Balice-Gordon RJ.

PLoS One. 2010 Oct 29;5(10):e13743. doi: 10.1371/journal.pone.0013743.

23.

Insights into Cdc13 dependent telomere length regulation.

Mason M, Skordalakes E.

Aging (Albany NY). 2010 Oct;2(10):731-4.

24.

Cdc13 N-terminal dimerization, DNA binding, and telomere length regulation.

Mitchell MT, Smith JS, Mason M, Harper S, Speicher DW, Johnson FB, Skordalakes E.

Mol Cell Biol. 2010 Nov;30(22):5325-34. doi: 10.1128/MCB.00515-10. Epub 2010 Sep 13.

25.

Structural basis for telomerase catalytic subunit TERT binding to RNA template and telomeric DNA.

Mitchell M, Gillis A, Futahashi M, Fujiwara H, Skordalakes E.

Nat Struct Mol Biol. 2010 Apr;17(4):513-8. doi: 10.1038/nsmb.1777. Epub 2010 Mar 28.

PMID:
20357774
26.

Disease mutations in Rab7 result in unregulated nucleotide exchange and inappropriate activation.

McCray BA, Skordalakes E, Taylor JP.

Hum Mol Genet. 2010 Mar 15;19(6):1033-47. doi: 10.1093/hmg/ddp567. Epub 2009 Dec 22.

27.

Asf1-like structure of the conserved Yaf9 YEATS domain and role in H2A.Z deposition and acetylation.

Wang AY, Schulze JM, Skordalakes E, Gin JW, Berger JM, Rine J, Kobor MS.

Proc Natl Acad Sci U S A. 2009 Dec 22;106(51):21573-8. doi: 10.1073/pnas.0906539106. Epub 2009 Dec 4.

28.

Telomerase structure paves the way for new cancer therapies.

Skordalakes E.

Future Oncol. 2009 Mar;5(2):163-7. doi: 10.2217/14796694.5.2.163. Review.

PMID:
19284375
29.

Telomerase and the benefits of healthy living.

Skordalakes E.

Lancet Oncol. 2008 Nov;9(11):1023-4. doi: 10.1016/S1470-2045(08)70266-3. No abstract available.

PMID:
19012852
30.

Structure of the Tribolium castaneum telomerase catalytic subunit TERT.

Gillis AJ, Schuller AP, Skordalakes E.

Nature. 2008 Oct 2;455(7213):633-7. doi: 10.1038/nature07283. Epub 2008 Aug 31.

PMID:
18758444
31.

Function and structure of a prokaryotic formylglycine-generating enzyme.

Carlson BL, Ballister ER, Skordalakes E, King DS, Breidenbach MA, Gilmore SA, Berger JM, Bertozzi CR.

J Biol Chem. 2008 Jul 18;283(29):20117-25. doi: 10.1074/jbc.M800217200. Epub 2008 Apr 4.

32.
33.
34.
35.

Structural mechanism of inhibition of the Rho transcription termination factor by the antibiotic bicyclomycin.

Skordalakes E, Brogan AP, Park BS, Kohn H, Berger JM.

Structure. 2005 Jan;13(1):99-109.

36.

Structure and function of the conserved core of histone deposition protein Asf1.

Daganzo SM, Erzberger JP, Lam WM, Skordalakes E, Zhang R, Franco AA, Brill SJ, Adams PD, Berger JM, Kaufman PD.

Curr Biol. 2003 Dec 16;13(24):2148-58.

37.
38.

A robust and scalable microfluidic metering method that allows protein crystal growth by free interface diffusion.

Hansen CL, Skordalakes E, Berger JM, Quake SR.

Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16531-6. Epub 2002 Dec 16.

39.

Inhibition of human alpha-thrombin by a phosphonate tripeptide proceeds via a metastable pentacoordinated phosphorus intermediate.

Skordalakes E, Dodson GG, Green DS, Goodwin CA, Scully MF, Hudson HR, Kakkar VV, Deadman JJ.

J Mol Biol. 2001 Aug 17;311(3):549-55.

PMID:
11493008
40.

Bifunctional peptide boronate inhibitors of thrombin: crystallographic analysis of inhibition enhanced by linkage to an exosite 1 binding peptide.

Skordalakes E, Elgendy S, Goodwin CA, Green D, Scully MF, Kakkar VV, Freyssinet JM, Dodson G, Deadman JJ.

Biochemistry. 1998 Oct 13;37(41):14420-7.

PMID:
9772168
41.

Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin.

Deadman JJ, Elgendy S, Goodwin CA, Green D, Baban JA, Patel G, Skordalakes E, Chino N, Claeson G, Kakkar VV, et al.

J Med Chem. 1995 Apr 28;38(9):1511-22.

PMID:
7739010

Supplemental Content

Loading ...
Support Center